From our patients´ first visit to the Digestive Tract Tumours Department, the best diagnostic and therapeutic plan is created for them. We also plan and organise their own and their family´s overall care. This allows us to provide the specific services we offer with efficiency, guaranteeing the optimum care for all our patients.
In the last decade, specific discoveries have been made in molecular biology about lung cancer, allowing new drugs to be developed, which are not only more efficient for certain groups of patients but have also changed the natural history of this cancer and allowed more substantial results to be obtained, with a better response to treatments and a higher survival rate worldwide.
In early stages, a thoracoscopy is a less invasive surgery option.
When it is confirmed that the tumour and disease are localised, it is possible to plan a surgical procedure in a high percentage of cases. If the disease has spread, it is probably no longer possible to use surgery.
It is important to determine, with respiratory function testing, if the patient is healthy enough to be operated on. Respiratory reserves after surgery are analysed.
There are various surgical procedures: lobectomy, pneumonectomy, segmentectomy or wedge resection.
Currently, a less invasive procedure is used in early stages: thoracoscopy. A small camera is positioned in the chest cavity which allows the surgeon to see the tumour. As a result, the incisions made are smaller and the recovery period is shorter.
Conventional chemotherapy is complemented with biological agents.
There are two different treatments depending on whether the carcinoma is microlithic or not.
For microlithic lung or small cell carcinomas, chemotherapy is used from the start and as soon as possible.
In non-microlithic lung carcinomas, there are three possible uses of chemotherapy.
There is not just one type of chemotherapy, along with conventional chemotherapy agents (cytotoxic drugs), we also have biological agents that act on specific molecular targets in the tumour.
We have all the necessary resources for safely using high level radiation on patients.
85% of lung tumours are microlithic carcinomas, for which radiotherapy is fundamental in controlling the disease.
Radiation treatment for a lung carcinoma is a clinical challenge where, preferably, special radiation techniques must be applied (like RT3D with a multilayer collimator or intensity modulated radiotherapy) since one of the prognosis factors linked to the patient´s treatment depends on the possibility of administering high doses of radiation on the tumour, as safely as possible.
For small lung tumours (less than 3-4cm) in inoperable patients, it is also possible to use stereotactic radiotherapy – SBRT (Stereotactic Body Radiation Therapy), which offers very good results in controlling the disease, with very few secondary effects.